Signant Health Appoints Specialist Physician and Clinical Research Expert Dr. Graham C. Ellis as Clinical Vice President to Strengthen Metabolic Disease and Diabetes Trial Capabilities

PHILADELPHIA, April 2, 2026 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today the appointment of Dr. Graham C. Ellis as Clinical Vice President. With more than 25 years of experience as a specialist physician and clinical researcher in diabetes, endocrinology, and metabolic disease, Dr. Ellis brings extensive scientific depth and a distinguished track record as a Principal Investigator across more than 150 international Phase 2–4 clinical trials. His appointment strengthens Signant's capabilities in supporting sponsors developing treatments in metabolic disease, obesity, and related therapeutic areas.

"I have spent my career at the intersection of clinical medicine and drug development, where the quality of scientific evidence directly shapes patient outcomes," said Dr. Ellis. "Signant's focus on rigorous evidence generation and its deep operational expertise in clinical outcome assessments make it uniquely positioned to support sponsors in complex therapeutic areas like diabetes and metabolic disease. I look forward to working with the team to further advance how we design, measure, and deliver high-quality data in these trials."

Dr. Ellis earned degrees in medical biochemistry and internal medicine from the University of Stellenbosch, South Africa. He founded and led HCTC, a prominent clinical research center in South Africa, before going on to serve as Executive Director of Medical Science and Strategy at PPD, the clinical research business of Thermo Fisher Scientific, where he oversaw the diabetes and metabolic disease portfolio. He has also served on a global expert panel for a recently completed GLP-1 cardiovascular outcomes trial in non-diabetic obese subjects, one of the most closely watched study designs in metabolic disease research today.

In his new role at Signant, Dr. Ellis will support the company's scientific and clinical capabilities across metabolic disease, diabetes, obesity, and related indications – therapeutic areas where endpoint selection, patient-reported outcomes, and the integrity of clinical measurement are increasingly central to regulatory submissions. His experience as an investigator across a broad range of Phase 2–4 studies, including GLP-1 cardiovascular outcomes trials and large multinational diabetes programs, positions him to work directly with sponsor teams on the design and execution of evidence-generation strategies.

"Graham's appointment reflects our continued investment in building the scientific expertise that our customers need as they navigate increasingly demanding regulatory environments," commented Dawie Wessels, Signant's chief medical officer. "His background as both a clinician and a seasoned clinical researcher gives him a perspective that is directly relevant to the challenges sponsors face in metabolic disease and diabetes trials. We're delighted to welcome him to the Signant team."

To learn more about Signant Health and its full range of evidence generation solutions, visit: https://www.signanthealth.com/ 

About Signant Health

Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com

Contact:
Heather Bilinski
[email protected]
+1 610.400.4141

SOURCE Signant Health